[go: up one dir, main page]

DK1347971T3 - Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien - Google Patents

Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien

Info

Publication number
DK1347971T3
DK1347971T3 DK01991416T DK01991416T DK1347971T3 DK 1347971 T3 DK1347971 T3 DK 1347971T3 DK 01991416 T DK01991416 T DK 01991416T DK 01991416 T DK01991416 T DK 01991416T DK 1347971 T3 DK1347971 T3 DK 1347971T3
Authority
DK
Denmark
Prior art keywords
thiazolyl
inhibitors
tec family
tyrosine kinases
compounds
Prior art date
Application number
DK01991416T
Other languages
Danish (da)
English (en)
Inventor
Steven H Spergel
John Witayk
Joel C Barrish
Jagabandhu Das
Steven B Kanner
Chunjian Liu
Arthur M P Doweyko
Joseph A Furch
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1347971T3 publication Critical patent/DK1347971T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
DK01991416T 2000-12-21 2001-12-19 Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien DK1347971T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25783000P 2000-12-21 2000-12-21

Publications (1)

Publication Number Publication Date
DK1347971T3 true DK1347971T3 (da) 2006-05-15

Family

ID=22977933

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01991416T DK1347971T3 (da) 2000-12-21 2001-12-19 Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien

Country Status (13)

Country Link
US (6) US6706717B2 (fr)
EP (1) EP1347971B1 (fr)
JP (1) JP4405726B2 (fr)
AT (1) ATE318812T1 (fr)
AU (2) AU3113902A (fr)
CA (1) CA2433018A1 (fr)
CY (1) CY1105349T1 (fr)
DE (1) DE60117605T2 (fr)
DK (1) DK1347971T3 (fr)
ES (1) ES2257461T3 (fr)
HU (1) HUP0303538A2 (fr)
PT (1) PT1347971E (fr)
WO (1) WO2002050071A1 (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2002233271A1 (en) * 2000-12-20 2002-07-01 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
WO2004014904A1 (fr) * 2002-08-09 2004-02-19 Pfizer Inc. Composes 2-(heteroaryl)-aminothiazole antiproliferatifs, compositions pharmaceutiques et leurs procedes d'utilisation
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
JP2006507302A (ja) * 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
WO2004080996A1 (fr) * 2003-03-07 2004-09-23 Eli Lilly And Company Antagonistes des recepteurs opioides
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es) 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
US7915443B2 (en) 2006-11-16 2011-03-29 Allergan, Inc. Sulfoximines as kinase inhibitors
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
ATE485300T1 (de) * 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
WO2006065946A1 (fr) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones utiles comme inhibiteurs de proteine kinases de la famille tec pour le traitement de maladies inflammatoires, proliferatives et a mediation immunologique
CA2595834C (fr) 2005-02-04 2013-04-30 Astrazeneca Ab Derives de pyrazolylaminopyridine employes en tant qu'inhibiteurs de kinase
JP2009513563A (ja) * 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
EP2388259A1 (fr) 2005-10-28 2011-11-23 AstraZeneca AB Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu'inhibiteurs de tyrosine kinases dans le cadre d'un traitement anticancereux
EP1971597A2 (fr) * 2005-12-12 2008-09-24 Genelabs Technologies, Inc. Composés antiviraux n-(noyau aromatique à 5 chaînons) amido
JP2009521461A (ja) * 2005-12-22 2009-06-04 アイカジェン， インコーポレイテッド カルシウムチャネルアンタゴニスト
EP1966174A1 (fr) * 2005-12-22 2008-09-10 AstraZeneca AB Composes chimiques
WO2007136790A2 (fr) * 2006-05-18 2007-11-29 Mannkind Corporation Inhibiteurs de kinases intracellulaires
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006044696A1 (de) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
US8148400B2 (en) * 2006-12-20 2012-04-03 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors
JP5286281B2 (ja) * 2007-01-05 2013-09-11 ブリストル−マイヤーズ スクイブ カンパニー アミノピラゾールキナーゼ阻害剤
WO2008124757A1 (fr) * 2007-04-10 2008-10-16 Bristol-Myers Squibb Company Composés de thiazolyle en tant qu'inhibiteurs de kinase
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
CN101835765B (zh) 2007-08-03 2013-05-29 罗马克实验室有限公司 烷基磺酰基取代的噻唑化物类化合物
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
US8791146B2 (en) 2008-05-29 2014-07-29 Bayer Intellectual Property Gmbh 2-alkoxy-substituted dicyanopyridines and their use
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
CA2761876C (fr) * 2009-05-12 2017-01-03 Romark Laboratories L.C. Composes haloalkyl heteroaryl benzamide
KR20180032689A (ko) 2009-06-26 2018-03-30 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
ES2743153T3 (es) 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN102883607B (zh) * 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
EP2568809A4 (fr) 2010-05-12 2013-11-06 Univ Vanderbilt Potentialisateurs allostériques hétérocycliques sulfonés du mglur4, compositions associées et méthodes de traitement d'un dysfonctionnement neurologique
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
CA3030689C (fr) * 2010-08-24 2021-03-02 Gtx, Inc. Composes utilises dans le traitement du cancer
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
WO2013148603A1 (fr) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Dérivés de cinnoline en tant qu'en tant qu'inhibiteurs de la btk
WO2013153539A1 (fr) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Composés tricycliques à titre d'inhibiteurs de kinases tec
CN103724349A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN104003956A (zh) * 2013-02-27 2014-08-27 中国药科大学 噻唑类化合物、其制备方法与其在制药中的用途
EP2964028A4 (fr) 2013-03-05 2017-06-07 University of Tennessee Research Foundation Composés pour le traitement du cancer
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
BR112015025260B1 (pt) 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
HRP20221262T1 (hr) 2013-09-13 2022-12-09 Beigene Switzerland Gmbh Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
EP3060218A4 (fr) 2013-10-25 2017-07-19 Pharmacyclics LLC Méthodes de traitement et de prévention d'une maladie du greffon contre l'hôte
AU2015240518A1 (en) * 2014-04-05 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
ES2815374T3 (es) 2014-05-06 2021-03-29 Oncternal Therapeutics Inc Compuestos para el tratamiento del cáncer
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CA2972239A1 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CA3002551A1 (fr) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1
CN105017174B (zh) * 2015-07-13 2017-03-15 南华大学 N‑（4‑烷基‑5‑苄基噻唑‑2‑基）烯酰胺及其制备方法与应用
AU2016317049A1 (en) 2015-08-31 2018-03-15 Pharmacyclics Llc BTK inhibitor combinations for treating multiple myeloma
EP4019515A1 (fr) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
TWI620748B (zh) * 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
CA3019134C (fr) 2016-03-31 2024-04-23 Takeda Pharmaceutical Company Limited Complexes isoquinoleinyle-triazolone
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
WO2018033853A2 (fr) 2016-08-16 2018-02-22 Beigene, Ltd. Forme cristalline de (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényle)-4,5,6,7-tétra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa préparation et ses utilisations
TWI739887B (zh) 2016-08-19 2021-09-21 英屬開曼群島商百濟神州有限公司 使用包含btk抑制劑的組合產品治療癌症
AU2017326558B2 (en) 2016-09-19 2022-01-06 Mei Pharma, Inc. Combination therapy
JOP20190052A1 (ar) * 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
MX392031B (es) * 2016-11-03 2025-03-21 Corvus Pharmaceuticals Inc Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2
MX2019005029A (es) 2016-11-03 2019-10-24 Juno Therapeutics Inc Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk).
US10479786B2 (en) 2016-12-13 2019-11-19 Princeton Drug Discovery, Inc Protein kinase inhibitors
EP3573989A4 (fr) 2017-01-25 2020-11-18 Beigene, Ltd. Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, préparation et utilisations associées
CA3053418A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composes et methodes de traitement de l'angiocholite biliaire primitive
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
WO2019013562A1 (fr) 2017-07-12 2019-01-17 주식회사 대웅제약 Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
KR102384924B1 (ko) 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019034009A1 (fr) 2017-08-12 2019-02-21 Beigene, Ltd. Inhibiteur de btk ayant une double sélectivité améliorée
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
CA3098497A1 (fr) 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Polytherapie d'une therapie par lymphocytes t a recepteur antigenique chimerique (car) et d'un inhibiteur de btk
CA3102136A1 (fr) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methodes de traitement de troubles associes au recepteur s1p1<sb />
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
WO2020045941A1 (fr) 2018-08-27 2020-03-05 주식회사 대웅제약 Nouveau dérivé d'amine hétérocyclique et composition pharmaceutique le comprenant
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
TWI856111B (zh) 2019-06-10 2024-09-21 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
JOP20220199A1 (ar) 2020-02-26 2023-01-30 Daewoong Pharmaceutical Co Ltd طريقة لتحضير مشتقات أمين حلقي غير متجانس
AU2021297778A1 (en) * 2020-06-23 2022-11-24 Dana-Farber Cancer Institute, Inc. Compounds for targeted degradation of interleukin-2-inducible T-cell kinase and methods of use
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
WO2024123175A1 (fr) 2022-12-06 2024-06-13 Erasmus University Medical Center Rotterdam Compositions pour le traitement de cancers résistants à la thérapie par blocage de point de contrôle immunitaire

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
TW205041B (fr) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
FR2742153B1 (fr) * 1995-12-12 1998-02-13 Innothera Lab Sa Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP0928790B1 (fr) 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Dérivés du thiazole
SI0928793T1 (en) 1998-01-02 2002-10-31 F. Hoffmann-La Roche Ag Thiazole derivatives
DE69923681T2 (de) 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
JP2002520324A (ja) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド 新規な血管形成インヒビター
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
PT1123283E (pt) 1998-10-22 2004-09-30 Hoffmann La Roche Derivados de tiazole
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
JP3498600B2 (ja) 1998-11-09 2004-02-16 三菱電機株式会社 キャリア位相推定装置とキャリア位相推定装置を用いた復調器
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP2308833A3 (fr) * 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Inhibiteurs de kinase de tyrosine de protéine cyclique
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
HUP0202682A3 (en) * 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
SE9904177D0 (sv) 1999-11-18 1999-11-18 Astra Ab Novel compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.

Also Published As

Publication number Publication date
CA2433018A1 (fr) 2002-06-27
US20040067989A1 (en) 2004-04-08
US20040077695A1 (en) 2004-04-22
DE60117605D1 (de) 2006-04-27
PT1347971E (pt) 2006-06-30
EP1347971B1 (fr) 2006-03-01
US6953795B2 (en) 2005-10-11
US20040110752A1 (en) 2004-06-10
JP4405726B2 (ja) 2010-01-27
CY1105349T1 (el) 2010-03-03
HUP0303538A2 (hu) 2005-02-28
US7241781B2 (en) 2007-07-10
AU2002231139B2 (en) 2007-03-22
US6958336B2 (en) 2005-10-25
US6706717B2 (en) 2004-03-16
AU3113902A (en) 2002-07-01
US20060030598A1 (en) 2006-02-09
ES2257461T3 (es) 2006-08-01
US7037926B2 (en) 2006-05-02
WO2002050071A1 (fr) 2002-06-27
EP1347971A1 (fr) 2003-10-01
US6956045B2 (en) 2005-10-18
DE60117605T2 (de) 2006-12-07
ATE318812T1 (de) 2006-03-15
US20040067990A1 (en) 2004-04-08
JP2005506950A (ja) 2005-03-10
US20030069238A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
DK1347971T3 (da) Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
GEP20074234B (en) Cyclic protein tyrosine kinase inhibitors
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DK1638941T3 (da) Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
CA2366932A1 (fr) Inhibiteurs cycliques de proteine tyrosine kinase
ATE554087T1 (de) Neue kinaseinhibitoren
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
MEP20908A (en) Thienopyrazoles
BRPI0407841A (pt) inibidores heterocìclicos de quinase
WO2006037032A3 (fr) Promedicaments d&#39;inhibiteurs de la proteine tyrosine kinase
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
EP1671969A3 (fr) inhibiteurs thiazolyl des kinases tyrosine de la famille TEC
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren